HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jeffery D Molkentin Selected Research

Cardiomegaly (Heart Hypertrophy)

12/2018Myofibroblast-Specific TGFβ Receptor II Signaling in the Fibrotic Response to Cardiac Myosin Binding Protein C-Induced Cardiomyopathy.
6/2017Caveolae-localized L-type Ca2+ channels do not contribute to function or hypertrophic signalling in the mouse heart.
12/2016Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DUSPs).
10/2016Inositol 1,4,5-trisphosphate-mediated sarcoplasmic reticulum-mitochondrial crosstalk influences adenosine triphosphate production via mitochondrial Ca2+ uptake through the mitochondrial ryanodine receptor in cardiac myocytes.
11/2015TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.
10/2014RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis.
7/2014Genetic manipulation of the cardiac mitochondrial phosphate carrier does not affect permeability transition.
1/2014Overexpression of the Na+/K+ ATPase α2 but not α1 isoform attenuates pathological cardiac hypertrophy and remodeling.
6/2013Parsing good versus bad signaling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells.
4/2013Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jeffery D Molkentin Research Topics

Disease

53Cardiomegaly (Heart Hypertrophy)
12/2018 - 03/2002
52Hypertrophy
10/2021 - 03/2002
42Heart Failure
01/2022 - 04/2002
29Fibrosis (Cirrhosis)
12/2018 - 04/2002
18Cardiomyopathies (Cardiomyopathy)
01/2019 - 02/2003
16Necrosis
05/2016 - 03/2005
15Myocardial Infarction
01/2018 - 01/2004
14Heart Diseases (Heart Disease)
11/2017 - 03/2002
14Muscular Dystrophies (Muscular Dystrophy)
05/2016 - 06/2006
12Ischemia
01/2020 - 01/2004
9Reperfusion Injury
01/2021 - 01/2004
9Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
01/2017 - 03/2004
8Infarction (Infarctions)
04/2014 - 04/2004
6Body Weight (Weight, Body)
01/2021 - 04/2002
6Rupture
01/2020 - 08/2013
6Inflammation (Inflammations)
10/2017 - 04/2005
5Ventricular Remodeling
01/2018 - 08/2007
5Neoplasms (Cancer)
01/2012 - 07/2002
5Infections
03/2011 - 03/2002
4Sudden Death
01/2017 - 09/2003
4Pancreatitis
01/2016 - 04/2012
4Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy)
01/2011 - 06/2006
3Atrophy
01/2021 - 01/2010
3Cardiac Arrhythmias (Arrythmia)
01/2020 - 09/2003
3Cicatrix (Scar)
01/2018 - 01/2016
3Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
05/2016 - 03/2007
3Thrombosis (Thrombus)
07/2010 - 02/2008
2Insulin Resistance
11/2020 - 02/2013
2Type 2 Diabetes Mellitus (MODY)
11/2020 - 02/2010
2Hyperglycemia
01/2020 - 02/2010
2Pulmonary Hypertension
12/2019 - 05/2003
2Fatigue
11/2018 - 04/2015

Drug/Important Bio-Agent (IBA)

52CalcineurinIBA
11/2015 - 03/2002
31Proteins (Proteins, Gene)FDA Link
01/2020 - 04/2002
18CalciumIBA
05/2016 - 03/2002
16Transcription Factors (Transcription Factor)IBA
01/2020 - 08/2002
12Mitochondrial Permeability Transition PoreIBA
01/2021 - 09/2007
12Protein Isoforms (Isoforms)IBA
01/2015 - 12/2002
11Cyclophilins (Cyclophilin)IBA
01/2021 - 03/2005
8Mitogen-Activated Protein KinasesIBA
11/2020 - 04/2004
8Phosphotransferases (Kinase)IBA
01/2020 - 11/2002
8Phosphoric Monoester Hydrolases (Phosphatases)IBA
12/2019 - 03/2002
8PeriostinIBA
01/2017 - 08/2007
7CytokinesIBA
10/2018 - 04/2005
7Sarcoglycans (beta Sarcoglycan)IBA
12/2014 - 06/2006
6CollagenIBA
01/2021 - 02/2009
6Angiotensin IIIBA
11/2020 - 11/2002
6DNA (Deoxyribonucleic Acid)IBA
12/2019 - 01/2004
6DystrophinIBA
05/2016 - 01/2007
6Protein Kinases (Protein Kinase)IBA
01/2015 - 08/2006
6Transforming Growth Factors (Transforming Growth Factor)IBA
12/2014 - 02/2011
6Isoproterenol (Isoprenaline)FDA LinkGeneric
01/2012 - 05/2003
6Cyclosporine (Ciclosporin)FDA LinkGeneric
02/2011 - 04/2002
6Phosphoprotein Phosphatases (Phosphatases, Protein)IBA
02/2009 - 01/2004
5Calmodulin (Calcium-Dependent Activator Protein)IBA
01/2020 - 05/2002
5Protein Kinase CIBA
01/2018 - 02/2007
5p38 Mitogen-Activated Protein KinasesIBA
08/2017 - 05/2003
5LuciferasesIBA
09/2015 - 05/2003
5Histone Deacetylases (Histone Deacetylase)IBA
04/2013 - 03/2006
4RNA (Ribonucleic Acid)IBA
10/2021 - 11/2017
4Messenger RNA (mRNA)IBA
01/2020 - 02/2006
4DesminIBA
10/2018 - 12/2010
4TamoxifenFDA LinkGeneric
01/2017 - 02/2005
4Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2016 - 11/2002
4MyostatinIBA
01/2016 - 06/2006
4Adenosine Triphosphate (ATP)IBA
01/2016 - 03/2008
41- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
01/2016 - 02/2008
4Tacrolimus (Prograf)FDA LinkGeneric
09/2015 - 03/2002
4Calcineurin InhibitorsIBA
09/2015 - 03/2002
4Peptides (Polypeptides)IBA
10/2011 - 02/2006
4Phenylephrine (Neo-Synephrine)FDA LinkGeneric
07/2011 - 05/2003
4cysteine and glycine-rich protein 3IBA
08/2006 - 03/2004
3Complementary DNA (cDNA)IBA
01/2021 - 02/2003
3Reactive Oxygen Species (Oxygen Radicals)IBA
01/2020 - 03/2011
3IntegrinsIBA
01/2019 - 08/2010
3Transforming Growth Factor beta (TGF-beta)IBA
10/2018 - 02/2006
3Crystallins (Crystallin)IBA
10/2018 - 09/2014
3ruboxistaurinIBA
12/2017 - 07/2009
3Creatine Kinase (Creatine Phosphokinase)IBA
03/2016 - 03/2011
3ChemokinesIBA
01/2016 - 04/2005
3Pharmaceutical PreparationsIBA
01/2016 - 02/2009
3Adenosine Triphosphatases (ATPase)IBA
01/2015 - 04/2009
3G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
02/2013 - 11/2002
3Insulin (Novolin)FDA Link
01/2013 - 01/2004
3Serine (L-Serine)FDA Link
07/2011 - 10/2004
3salicylhydroxamic acid (SHAM)IBA
02/2011 - 08/2007
3transcription factor NF-AT c3IBA
10/2008 - 06/2003
2Dual-Specificity PhosphatasesIBA
11/2020 - 04/2004
2Glucose (Dextrose)FDA LinkGeneric
11/2020 - 02/2011
2Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
01/2020 - 03/2006
2Transforming Growth Factor-beta Type II ReceptorIBA
12/2018 - 10/2018
2Carrier Proteins (Binding Protein)IBA
12/2018 - 01/2016
2Extracellular Matrix ProteinsIBA
01/2018 - 01/2009
2Glycoproteins (Glycoprotein)IBA
01/2018 - 03/2016
2Fibronectins (Fibronectin)IBA
01/2018 - 01/2012
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
08/2017 - 10/2014
2Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA
01/2016 - 06/2011
2Bile Acids and Salts (Bile Acids)IBA
01/2016 - 01/2013
2Enzyme Precursors (Zymogens)IBA
01/2016 - 04/2012

Therapy/Procedure

6Therapeutics
01/2021 - 05/2004